Menu
About Us
Company Overview
Corporate Culture
Manufacturing Base
MAH
Drug Development to Commercialization
Milestones
Code of Business Ethics
Services
Services
Providing reliable CDMO solutions with excellent quality and professional services
ADC Platform
Overview
ADC R&D Service Platform
Conjugation Process
Development
and Optimization
Drug Product
Formulation and
Lyophilization Process
Analysis Services
Antibody Manufacturing
ADC Drug Substance
Manufacturing
Lyophilized Drug
Product Manufacture
Protein/Antibody Platform
Overview
Cell Culture
Process Development
Purification Process
Development
Drug Product
Formulation and
Lophilization Process
Analysis Services
GMP Manufacturing
Overview
Drug Substance
Manufacturing
Drug Product
Manufacturing
Process Characterization
/Process Validation
Technology Transfer
Overview
Technology Transfer
Quality
Overview
Quality Control
Quality Assurance
Regulatory Affairs
Overview
Service and Advantages
Investor Relations
Company Profile
Corporate Governance
Announcements and Circulars
The Listed Files
Financial Reports and ESG Reports
Company Promotion Materials
Investor Relations Query
Investor Relations Journal
News & Events
News
Events
Media Attention
Partner News
Resources
Technical Articles
Download Center
Join Us
Members of TOT
Join in TOT
Contact Us
EN
繁體
简体
EN
繁體
简体
Home
＜
News & Events
News & Events
News
Events
Media Attention
Partner News
2023
2021
2022
2023
2023.05
24
Congratulations! TOT BIOPHARM's CDMO partner Bioray’s application for clinical trial of BRY812 injection, a Class 1 new drug was accepted
Bioray, TOT BIOPHARMs CDMO partner, announced that its application for clinical trials of BRY812 injection, a class 1 innovative biological product independently developed by itself, has been accepted by NMPA. BRY812 is a novel antibody-drug conjugate (AD
«
1
»
The module is under construction